Q1 2026 snapshot: revenue holds steady while losses persist at SOPHiA GENETICS (SOPH)
SOPHiA GENETICS (SOPH) opened 2026 with Q1 revenue of US$21.7 million and a basic EPS loss of US$0.27, as the stock trades around US$5.02. The company has seen revenue move from US$17.8 million in Q1 2025 to US$21.7 million in Q1 2026, while trailing 12 month EPS sits at a loss of US$1.18. With margins still in the red and profitability not yet in sight, investors may focus on how far revenue growth can carry the story before losses and cash burn start to dominate the conversation.
See our full analysis for SOPHiA GENETICS.With the quarterly scorecard set, the next section lines these results up against the main narratives around SOPHiA GENETICS to see which views the numbers support and which they call into question.
See what the community is saying about SOPHiA GENETICS
US$81.2m trailing revenue, but losses of US$80.9m still weigh
- Over the last twelve months, SOPHiA GENETICS generated US$81.2 million in revenue and recorded a net loss of US$80.9 million, with trailing EPS at a loss of US$1.18.
- Bulls point to strong top line traction and higher value contracts, yet the trailing loss trend tests that optimism:
- Revenue on a trailing basis has moved from US$65.2 million in Q4 2024 to US$81.2 million in Q1 2026, while losses have also widened over the same window, with net loss moving from US$62.5 million to US$80.9 million.
- Even bullish assumptions that revenue could grow around the mid 20% range over the next few years sit against a current reality where five year losses have grown at about 2% per year and profitability is not expected within three years.
Bulls argue that recurring, higher value contracts and pharma deals can eventually make those US$80.9 million trailing losses worthwhile, but the current earnings profile shows just how much work is still ahead before that view can play out in the numbers 🐂 SOPHiA GENETICS Bull Case
Premium 4.4x P/S leaves little margin for execution slips
- The stock trades on a P/S of 4.4x, compared with 2.3x for the broader US Healthcare Services industry and 1.4x for peers, while analysts in the provided data point to an average price target of US$8.00 versus the current US$5.02 share price.
- Bears focus on the mix of rich sales multiple and persistent losses as a key risk:
- Losses have grown at roughly 2% per year over the past five years and trailing net loss of US$80.9 million is close to the full trailing revenue base, which leaves little support from current earnings to underpin the 4.4x P/S.
- With the company expected to remain loss making for at least three years in the provided forecast, critics argue the valuation is highly sensitive to any slowdown from the roughly 20.1% revenue growth rate that is being forecast off the recent run rate.
Skeptics see a setup where a 4.4x P/S and an US$8.00 analyst target leave the stock leaning heavily on growth forecasts despite the US$80.9 million trailing loss, which is exactly the tension the more cautious narrative focuses on 🐻 SOPHiA GENETICS Bear Case
Quarterly losses hover around US$19m despite improving EPS trend
- Q1 2026 net loss was US$19.3 million with a basic EPS loss of US$0.27, broadly similar to Q4 2025 net loss of US$19.2 million and EPS loss of US$0.28 even as quarterly revenue held near US$21.7 million in both periods.
- The balanced narrative that highlights improving efficiency sits against margins that are still deeply negative:
- From Q2 2025 to Q1 2026, revenue moved from US$18.3 million to US$21.7 million while quarterly losses stayed in a band of roughly US$19 million to US$22.4 million, which suggests higher revenue has not yet translated into a smaller absolute loss.
- Trailing EPS at a loss of US$1.18 and trailing net loss of US$80.9 million contrast with commentary around process improvements and cost discipline, showing that any efficiency gains have not yet shifted the company out of heavy loss making territory.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for SOPHiA GENETICS on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If this mix of optimism and concern feels familiar, that is the point: markets rarely offer a one sided story. Act quickly and review both sides of the ledger by checking the 2 key rewards and 1 important warning sign
Explore Alternatives
SOPHiA GENETICS is still recording heavy losses of around US$19.3 million per quarter and a trailing net loss of US$80.9 million despite higher revenue.
If you want ideas where profitability and valuation look more forgiving right now, take a few minutes to scan the 49 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com